Rhythm Pharmaceuticals announces public reimbursement for Imcivree (setmelanotide) in Canada in five provinces and under the Federal Non-Insured Health Benefits Program

5 November 2025 - Rhythm Pharmaceuticals today announced that it has entered into Product Listing Agreements in the provinces of Ontario, ...

Read more →

AbbVie's Vraylar (cariprazine) now publicly reimbursed in Alberta

15 September 2025 - AbbVie announced today that Alberta has listed Vraylar (cariprazine) on its Health Drug Formulary. ...

Read more →

Government of Canada signs bilateral agreement with Alberta to improve access to drugs for rare diseases

5 December 2024 - Today, the Honourable Mark Holland, Canada's Minister of Health, and the Honourable Adriana LaGrange, Alberta's Minister ...

Read more →

HLS announces reimbursement for Vascepa under Alberta's Provincial Drug Plan

29 July 2024 - With the addition of Alberta's public plan, Vascepa will be available to more than 90% of ...

Read more →

Alberta will cover pricey drug believed to extend and enhance lives of ALS patients

7 August 2023 - People diagnosed with ALS are usually given two to five years to live. ...

Read more →

Alberta’s import of children’s medication to cost taxpayers $80 million

9 March 2023 - Alberta taxpayers are on the hook for $80 million, after Health Minister Jason Copping finally revealed ...

Read more →

AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...

Read more →

Alberta expands access to cystic fibrosis drug Trikafta for children 6 to 11

11 July 2022 - Children with cystic fibrosis can now live 'longer, healthier and fuller lives,' says advocate. ...

Read more →

Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases

3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...

Read more →

Baqsimi (nasal glucagon), rescue treatment for severe hypoglycaemia now covered in British Colombia, Alberta & Saskatchewan

27 April 2022 - Lilly Canada is pleased to announce that as of 5 April 2022, Baqsimi (glucagon nasal powder) ...

Read more →

Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the non-insured health benefits program for patients prescribed Ajovy (fremanezumab) for the preventive treatment of migraine in adults

2 March 2022 - Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada. ...

Read more →

Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Alberta

3 November 2021 - First provincial public listing secured for both asthma medications. ...

Read more →

Alberta faces shortage of COVID-19 drug as global demand spikes

11 May 2021 - Provinces with highest case rates hit by shortage of medication for sickest patients. ...

Read more →

Alberta, Canada, begins mandating switches from originator to biosimilar Humira

6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...

Read more →

Alberta family waiting on approval for expensive, life-saving drug for young boy

23 March 2021 - Reign Johnston turned 2 on March 5. One of his grandpas and an uncle came to ...

Read more →